Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist
ANAB

ANAPTYSBIO (ANAB) stock: insider trades, news & valuation

Heavy selling
Close · Oct 9, 2026 $45.95 -0.6% on the day +116.9% over 12 months 52-week range $20.91 – $69.81

Share price and insider trades

ANAB closeInsider buyInsider sale
20406080NovDecJan 2026FebMarAprMayJunJulAugSepOctEEarnings release filed 2025-11-04EEarnings release filed 2026-01-09EEarnings release filed 2026-03-03EEarnings release filed 2026-05-12Sold $6,626 on 2025-12-18 · Eric J LoumeauSold $193,362 on 2025-12-23 · J. Anthony WareSold $249,372 on 2026-10-01 · Hollings RentonSold $460,000 on 2025-12-17 · Eric J LoumeauSold $530,568 on 2026-01-15 · Magda MarquetSold $540,000 on 2026-02-11 · Eric J LoumeauSold $1,012,950 on 2026-01-08 · Daniel Faga, Dennis Mulroy, Eric J Loumeau, Paul F. LizzulSold $1,041,172 on 2026-01-07 · Daniel Faga, Dennis Mulroy, Eric J Loumeau, Paul F. LizzulSold $1,085,000 on 2025-12-22 · Dennis Mulroy, Eric J Loumeau, Paul F. LizzulSold $1,089,222 on 2026-03-27 · Daniel FagaSold $1,119,309 on 2026-01-05 · Daniel Faga, Dennis Mulroy, Eric J Loumeau, Paul F. LizzulSold $1,158,467 on 2026-03-30 · John P. SchmidSold $1,266,251 on 2025-12-16 · Dennis Mulroy, Eric J Loumeau
Bought, 12 months$0
Sold, 12 months$9.8M
Insiders buying0
Insiders selling8

ANAPTYSBIO insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 8 sold $9.8M of ANAB stock on the open market.

ANAB insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q3 2025: $239K sold (1 trades)Q3 2025Q4 2025: $3.0M sold (10 trades)Q4 2025Q1 2026: $6.5M sold (31 trades)Q1 2026Q2 2026Q3 2026Q4 2026: $249K sold (1 trades)Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0$249K1
Q3 2026—0—0
Q2 2026—0—0
Q1 2026—0$6.5M31
Q4 2025—0$3.0M10
Q3 2025—0$239K1

Valuation, profit and volume

P/E (trailing)n/aSector median —
Market value— 
Profit margin—Revenue growth —
Volume vs. 50-day1.2×Last 5 sessions
Insiders' paper profit—On all tracked purchases —

Summary

Over the past 12 months, 0 ANAPTYSBIO, INC insiders reported open-market purchases totaling $0, while 8 insiders reported sales totaling $9.8M. 16 of 43 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

ANAB earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
May 12, 2026 +15.4% None -7.7%S&P +0.4% -10.6%
Mar 3, 2026 +3.4% Sold $540K +10.3%S&P -0.2% -4.7%
Jan 9, 2026 -12.4% Sold $6.2M +11.9%S&P +0.8% +12.7%
Nov 4, 2025 +4.1% None -0.1%S&P -0.8% +23.2%
Aug 6, 2025 -9.5% None -14.0%S&P +0.7% +7.5%
May 5, 2025 +3.1% None -5.1%S&P -1.4% +5.1%
Feb 27, 2025 +37.4% None -1.1%S&P -0.1% +12.7%
Nov 5, 2024 -43.0% None +11.4%S&P +3.7% +11.7%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

Insider transactions

Open-market purchases and sales.

Filed Insider Type Shares Price Value Since Score
Oct 2SEC Hollings RentonDirector Sell Plan 5,00010,995 held (−31%) $49.87 $249K -7.9% —
Apr 1SEC John P. SchmidDirector Sell 12,59639,671 held (−24%) $55.71 $702K -17.5% —
Apr 1SEC John P. SchmidDirector Sell 7,52732,144 held (−19%) $56.70 $427K -19.0% —
Apr 1SEC John P. SchmidDirector Sell 52231,622 held (−2%) $57.40 $30K -19.9% —
Mar 27SEC Daniel FagaCEO, President Sell 3,662506,902 held (−1%) $58.62 $215K -21.6% —
Mar 27SEC Daniel FagaCEO, President Sell 3,155499,103 held (−1%) $64.19 $203K -28.4% —
Mar 27SEC Daniel FagaCEO, President Sell 3,038496,065 held (−1%) $65.20 $198K -29.5% —
Mar 27SEC Daniel FagaCEO, President Sell 2,592502,258 held (−1%) $63.35 $164K -27.5% —
Mar 27SEC Daniel FagaCEO, President Sell 2,570510,564 held (−1%) $57.91 $149K -20.7% —
Mar 27SEC Daniel FagaCEO, President Sell 1,012504,850 held (−0%) $62.15 $63K -26.1% —
Mar 27SEC Daniel FagaCEO, President Sell 550505,862 held (−0%) $60.63 $33K -24.2% —
Mar 27SEC Daniel FagaCEO, President Sell 490506,412 held (−0%) $59.62 $29K -22.9% —
Mar 27SEC Daniel FagaCEO, President Sell 510513,134 held (−0%) $56.61 $29K -18.8% —
Mar 27SEC Daniel FagaCEO, President Sell 100495,965 held (−0%) $65.99 $7K -30.4% —
Feb 13SEC Eric J LoumeauGeneral Counsel Sell Plan 10,00012,835 held (−44%) $54.00 $540K -14.9% —
Jan 16SEC Magda MarquetDirector Sell 9,29011,640 held (−44%) $48.12 $447K -4.5% —
Jan 16SEC Magda MarquetDirector Sell 1,7109,930 held (−15%) $48.85 $84K -5.9% —
Jan 9SEC Daniel FagaCEO, President Sell 14,281479,344 held (−3%) $44.71 $639K +2.8% —
Jan 9SEC Paul F. LizzulChief Medical Officer Sell 3,65042,088 held (−8%) $44.71 $163K +2.8% —
Jan 9SEC Dennis MulroyCFO Sell 2,51521,852 held (−10%) $44.71 $112K +2.8% —
Jan 9SEC Eric J LoumeauGeneral Counsel Sell 2,21012,835 held (−15%) $44.71 $99K +2.8% —
Jan 8SEC Daniel FagaCEO, President Sell 9,202466,787 held (−2%) $45.11 $415K +1.9% —
Jan 8SEC Eric J LoumeauGeneral Counsel Sell Plan 5,28111,498 held (−31%) $45.38 $240K +1.3% —
Jan 8SEC Paul F. LizzulChief Medical Officer Sell 2,23537,213 held (−6%) $45.11 $101K +1.9% —
Jan 8SEC Eric J LoumeauGeneral Counsel Sell Plan 2,01716,779 held (−11%) $45.11 $91K +1.9% —
Jan 8SEC Dennis MulroyCFO Sell 1,90817,667 held (−10%) $45.11 $86K +1.9% —
Jan 8SEC Eric J LoumeauGeneral Counsel Sell Plan 1,8419,657 held (−16%) $46.13 $85K -0.4% —
Jan 8SEC Eric J LoumeauGeneral Counsel Sell Plan 5009,157 held (−5%) $47.23 $24K -2.7% —
Jan 6SEC Daniel FagaCEO, President Sell 15,309458,139 held (−3%) $43.26 $662K +6.2% —
Jan 6SEC Paul F. LizzulChief Medical Officer Sell 4,21933,303 held (−11%) $43.26 $183K +6.2% —
Jan 6SEC Dennis MulroyCFO Sell 3,36314,330 held (−19%) $43.26 $145K +6.2% —
Jan 6SEC Eric J LoumeauGeneral Counsel Sell 2,98313,251 held (−18%) $43.26 $129K +6.2% —
Dec 23SEC Eric J LoumeauGeneral Counsel Sell Plan 10,0008,947 held (−53%) $51.00 $510K -9.9% —
Dec 23SEC Dennis MulroyCFO Sell Plan 10,0009,401 held (−52%) $50.00 $500K -8.1% —
Dec 23SEC J. Anthony WareDirector Sell 3,9009,630 held (−29%) $49.58 $193K -7.3% —
Dec 23SEC Paul F. LizzulChief Medical Officer Sell Plan 1,50026,967 held (−5%) $50.00 $75K -8.1% —
Dec 18SEC Eric J LoumeauGeneral Counsel Sell Plan 10,0009,088 held (−52%) $46.00 $460K -0.1% —
Dec 18SEC Dennis MulroyCFO Sell Plan 9,36515,761 held (−37%) $44.62 $418K +3.0% —
Dec 18SEC Eric J LoumeauGeneral Counsel Sell Plan 8,30513,283 held (−38%) $44.68 $371K +2.8% —
Dec 18SEC Dennis MulroyCFO Sell Plan 6,3609,401 held (−40%) $45.21 $288K +1.6% —
Dec 18SEC Eric J LoumeauGeneral Counsel Sell Plan 4,1959,088 held (−32%) $45.24 $190K +1.6% —
Dec 18SEC Eric J LoumeauGeneral Counsel Sell Plan 1418,947 held (−2%) $46.99 $7K -2.2% —
Oct 1SEC Eric J LoumeauGeneral Counsel Sell Plan 8,2409,088 held (−48%) $29.00 $239K +58.4% —

Insiders at ANAPTYSBIO, INC

InsiderBoughtSoldLast filingScore
Eric J LoumeauGeneral Counsel — $3.0M Feb 13, 2026 —
Daniel FagaCEO, President — $2.8M Mar 27, 2026 —
Dennis MulroyCFO — $1.5M Jan 9, 2026 —
John P. SchmidDirector — $1.2M Apr 1, 2026 —
Magda MarquetDirector — $531K Jan 16, 2026 —
Paul F. LizzulChief Medical Officer — $522K Jan 9, 2026 —
Hollings RentonDirector — $249K Oct 2, 2026 —
J. Anthony WareDirector — $193K Dec 23, 2025 —

ANAB stock: common questions

Are ANAPTYSBIO, INC insiders buying ANAB stock?

In the past 12 months, 0 insiders reported open-market purchases of ANAB worth $0.

Are ANAPTYSBIO, INC insiders selling ANAB stock?

8 insiders reported sales worth $9.8M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is ANAB's 52-week range?

Over the past year ANAB has traded between $20.91 and $69.81. It last closed at $45.95 on Oct 9, 2026.